$CARM
Carisma Therapeutics Inc

2017 Q2 Form 10-Q Financial Statement

#000148500317000081 Filed on August 14, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2
Revenue $0.00 $277.0K
YoY Change -100.0% 142.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.240M $3.470M
YoY Change -35.45% 54.22%
% of Gross Profit
Research & Development $2.909M $3.298M
YoY Change -11.8% -47.39%
% of Gross Profit
Depreciation & Amortization $90.00K $40.00K
YoY Change 125.0% -55.56%
% of Gross Profit
Operating Expenses $7.350M $6.769M
YoY Change 8.58% -20.51%
Operating Profit -$7.350M -$6.492M
YoY Change 13.22% -22.73%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $34.00K $1.000K
YoY Change 3300.0% -99.93%
Pretax Income -$7.320M -$6.490M
YoY Change 12.79% -6.08%
Income Tax
% Of Pretax Income
Net Earnings -$7.316M -$6.491M
YoY Change 12.71% -6.01%
Net Earnings / Revenue -2343.32%
Basic Earnings Per Share -$0.33
Diluted Earnings Per Share -$296.5K -$0.33
COMMON SHARES
Basic Shares Outstanding 24.70M shares 19.88M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.80M $8.500M
YoY Change 85.88% -84.11%
Cash & Equivalents $15.75M $8.484M
Short-Term Investments
Other Short-Term Assets $700.0K $400.0K
YoY Change 75.0% -55.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $16.46M $8.834M
YoY Change 86.3% -83.77%
LONG-TERM ASSETS
Property, Plant & Equipment $632.0K $314.0K
YoY Change 101.27% -45.86%
Goodwill $17.37M
YoY Change
Intangibles $60.50M
YoY Change
Long-Term Investments
YoY Change
Other Assets $77.00K $0.00
YoY Change -100.0%
Total Long-Term Assets $78.59M $433.0K
YoY Change 18050.12% -37.25%
TOTAL ASSETS
Total Short-Term Assets $16.46M $8.834M
Total Long-Term Assets $78.59M $433.0K
Total Assets $95.05M $9.267M
YoY Change 925.66% -83.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.245M $1.855M
YoY Change -32.88% -1.33%
Accrued Expenses $2.492M $1.153M
YoY Change 116.13% 86.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $3.855M $3.008M
YoY Change 28.16% -45.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $148.0K $73.00K
YoY Change 102.74% -55.49%
Total Long-Term Liabilities $148.0K $73.00K
YoY Change 102.74% -55.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.855M $3.008M
Total Long-Term Liabilities $148.0K $73.00K
Total Liabilities $4.003M $3.081M
YoY Change 29.93% -45.33%
SHAREHOLDERS EQUITY
Retained Earnings -$136.7M -$139.3M
YoY Change -1.86% 32.41%
Common Stock $25.00K $20.00K
YoY Change 25.0% 5.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.91M $6.173M
YoY Change
Total Liabilities & Shareholders Equity $95.05M $9.267M
YoY Change 925.66% -83.19%

Cashflow Statement

Concept 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$7.316M -$6.491M
YoY Change 12.71% -6.01%
Depreciation, Depletion And Amortization $90.00K $40.00K
YoY Change 125.0% -55.56%
Cash From Operating Activities -$4.510M -$5.010M
YoY Change -9.98% -44.52%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$10.00K
YoY Change
Cash From Investing Activities -$10.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 70.00K
YoY Change -100.0% -99.59%
NET CHANGE
Cash From Operating Activities -4.510M -5.010M
Cash From Investing Activities -10.00K 0.000
Cash From Financing Activities 0.000 70.00K
Net Change In Cash -4.520M -4.940M
YoY Change -8.5% -162.22%
FREE CASH FLOW
Cash From Operating Activities -$4.510M -$5.010M
Capital Expenditures $0.00
Free Cash Flow -$5.010M
YoY Change -42.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Licenses Revenue
LicensesRevenue
0 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24700746 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
dei Trading Symbol
TradingSymbol
EBIO
CY2017Q2 ebio Working Capital Net
WorkingCapitalNet
12600000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1667000 USD
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1245000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1774000 USD
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2492000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
413000 USD
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
206000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
161963000 USD
CY2017Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162564000 USD
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3240757 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3240757 shares
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2905336 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2905336 shares
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
88000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
5000 USD
CY2016Q4 us-gaap Assets
Assets
104097000 USD
CY2017Q2 us-gaap Assets
Assets
95048000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
25927000 USD
CY2017Q2 us-gaap Assets Current
AssetsCurrent
16458000 USD
CY2016Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2017Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2200000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3700000 USD
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
45100000 USD
CY2017Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
48800000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36079000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8484000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25342000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15751000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-27595000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9591000 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24531964 shares
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24687456000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24531964 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24687456000 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
25000 USD
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
25000 USD
CY2016Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
852000 USD
CY2017Q2 us-gaap Construction Payable Current
ConstructionPayableCurrent
1757000 USD
CY2016Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
16335000 USD
CY2017Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
16335000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
425000 USD
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
93000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
174000 USD
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5000 USD
CY2017Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
114000 USD
CY2017Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
118000 USD
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
352000 USD
CY2016Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
13000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-102000 USD
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
476000 USD
CY2017Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5000 USD
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P11M1D
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5M1D
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.8339
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.7345
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0085
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0114
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
79000 USD
CY2016Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-915000 USD
CY2017Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3471000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5618000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2241000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4454000 USD
CY2016Q4 us-gaap Goodwill
Goodwill
16864000 USD
CY2017Q2 us-gaap Goodwill
Goodwill
17371000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
609000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-422000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-991000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
359000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-406000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-425000 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
4000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
126000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
200000 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
25000 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0 USD
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
60500000 USD
CY2017Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
60500000 USD
CY2016Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-247000 USD
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0 USD
us-gaap Interest Paid
InterestPaid
663000 USD
us-gaap Interest Paid
InterestPaid
0 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104097000 USD
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95048000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3980000 USD
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3855000 USD
CY2016Q2 us-gaap Licenses Revenue
LicensesRevenue
0 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
135000 USD
CY2017Q2 us-gaap Licenses Revenue
LicensesRevenue
0 USD
us-gaap Licenses Revenue
LicensesRevenue
425000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14036000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
69000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13559000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9705000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-6491000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14065000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-7316000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13377000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1023000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
34000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
6769000 USD
us-gaap Operating Expenses
OperatingExpenses
13548000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
7350000 USD
us-gaap Operating Expenses
OperatingExpenses
13937000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6492000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13042000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7350000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13512000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
157000 USD
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
53000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
77000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
148000 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
139000 USD
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
34000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
135000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
26000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
0 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Sales Revenue Net
SalesRevenueNet
425000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
796000 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
585000 USD
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
707000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
69000 USD
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
621000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1207000 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136700000 USD
CY2016Q2 us-gaap Revenues
Revenues
277000 USD
us-gaap Revenues
Revenues
506000 USD
CY2017Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
277000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
506000 USD
CY2017Q2 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
632000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
14124000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3298000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7930000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2909000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5783000 USD
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123311000 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136679000 USD
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
322000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
566000 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
942661 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
166887 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
248025 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2024468 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1965206 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.41
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.92
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1965206 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.92
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.28
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.85
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.85
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
140400 shares
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
38677000 USD
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
25910000 USD
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19874000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19756000 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24685000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24648000 shares
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
221000 USD
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
0 USD

Files In Submission

Name View Source Status
0001485003-17-000081-index-headers.html Edgar Link pending
0001485003-17-000081-index.html Edgar Link pending
0001485003-17-000081.txt Edgar Link pending
0001485003-17-000081-xbrl.zip Edgar Link pending
ebio-063017101.htm Edgar Link pending
ebio-063017x10q.htm Edgar Link pending
ebio-063017x311.htm Edgar Link pending
ebio-063017x312.htm Edgar Link pending
ebio-063017x321.htm Edgar Link pending
ebio-20170630.xml Edgar Link completed
ebio-20170630.xsd Edgar Link pending
ebio-20170630_cal.xml Edgar Link unprocessable
ebio-20170630_def.xml Edgar Link unprocessable
ebio-20170630_lab.xml Edgar Link unprocessable
ebio-20170630_pre.xml Edgar Link unprocessable
ebiologoa21.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending